Posted by Michael Wonder on 24 Nov 2020
ObsEva submits marketing authorisation application to the European Medicines Agency for Yselty (linzagolix) for the treatment of women with uterine fibroids
24 November 2020 - If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids.
ObsEva today announced the submission of a marketing authorisation application to the EMA for Yselty (linzagolix 100 mg and linzagolix 200 mg) for the management of heavy menstrual bleeding associated with uterine fibroids.
